To see the other types of publications on this topic, follow the link: Jennifer Johnston.
Journal articles on the topic 'Jennifer Johnston'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Jennifer Johnston.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Rosslyn, F. "The Importance of Being Irish: Jennifer Johnston." Cambridge Quarterly 32, no. 3 (September 1, 2003): 239–49. http://dx.doi.org/10.1093/camqtly/32.3.239.
Full text
2
Donovan, Katie. "Secret friendships ; forbidden relations in the novels of Jennifer Johnston." Études irlandaises 23, no. 1 (1998): 43–65. http://dx.doi.org/10.3406/irlan.1998.1428.
Full text
3
Kennedy-Andrews, Elmer. "Representations of the Jew in the Modern Irish Novel since Joyce." Irish University Review 43, no. 2 (November 2013): 307–26. http://dx.doi.org/10.3366/iur.2013.0082.
Full textAbstract:
This study reads the Semitic discourse in five modern Irish novels – Francis Stuart's Black List Section H (1971), Robert MacLiam Wilson's Manfred's Pain (1992), Robert Welch's Groundwork (1997), Jennifer Johnston's This is Not a Novel (2002), and John Banville's Shroud (2002) – for what it tells us about the cultural identity of modern Ireland, and for what it reveals of the psychohistory, and even the psychopathology, of Irishness hidden in these representations. The span of five novels allows some demonstration, first, of the ambivalence, rather than overt hostility or unqualified identification, which characterises this writing; and, second, of the striking variety and heterogeneity in the representation of ‘the Jew’ in contemporary Irish writing. Such unpredictability and contradictoriness in the construction of Jewish racial difference challenges or threatens both the national discourse which seeks to exert control over the unmanageable ‘reality’ of Ireland in terms of fixity, certainty, centredness, homogeneity, and the transcendent discourse of liberal universalism. That is, these novelists, in demonstrating the impossibility of fixing the indeterminate Jew as one thing or the other, reflect a more general crisis of representation, not only for the nation (Welch, Johnston), and the individual (Wilson, Stuart), but for epistemology itself (Banville).
4
Kerr, Rosalind. "Higginbotham, Jennifer, and Mark Albert Johnston, eds. Queering Childhood in Early Modern English Drama and Culture." Renaissance and Reformation 42, no. 1 (2019): 390. http://dx.doi.org/10.7202/1064546ar.
Full text
5
Reisman, Mara. "Redefining Family in Jennifer Johnston's Foolish Mortals." College Literature 45, no. 3 (2018): 516–42. http://dx.doi.org/10.1353/lit.2018.0029.
Full text
6
Cardin, Bertrand. "Reflections in Jennifer Johnston's "This Is Not a Novel"." Canadian Journal of Irish Studies 31, no. 2 (2005): 34. http://dx.doi.org/10.2307/25515593.
Full text
7
Jennings, Eric, Hanna Diamond, Constance Pâris de Bollardière, and Jessica Lynne Pearson. "Book Reviews." French Politics, Culture & Society 36, no. 2 (June 1, 2018): 157–67. http://dx.doi.org/10.3167/fpcs.2018.360208.
Full textAbstract:
Ruth Ginio, The French Army and its African Soldiers: The Years of Decolonization (Lincoln: University of Nebraska Press, 2017). Valerie Deacon, The Extreme Right in the French Resistance: Members of the Cagoule and Corvignolles in the Second World War (Baton Rouge, LA: Louisiana State University Press, 2016). Daniella Doron, Jewish Youth and Identity in Postwar France: Rebuilding Family and Nation (Bloomington/Indianapolis: Indiana University Press, 2015).Jennifer Johnson, The Battle for Algeria: Sovereignty, Health Care, and Humanitarianism (Philadelphia: University of Pennsylvania Press, 2016).
8
Lyons, Amelia H. "Jennifer Johnson. The Battle for Algeria: Sovereignty, Health Care, and Humanitarianism." American Historical Review 122, no. 2 (March 30, 2017): 611–12. http://dx.doi.org/10.1093/ahr/122.2.611.
Full text
9
Stewart, Jessie. "Fashion and the Consumer, by Jennifer Yurchisin and Kim K.P. Johnson." Design and Culture 5, no. 2 (July 2013): 265–67. http://dx.doi.org/10.2752/175470813x13638640370977.
Full text
10
PANELLA, CRISTIANA. "Uncertain honor. Modern motherhood in an African crisis by Johnson-Hanks, Jennifer." Social Anthropology 15, no. 3 (June 28, 2008): 393–94. http://dx.doi.org/10.1111/j.0964-0282.2007.00023_14.x.
Full text
11
Feldman-Savelsberg, Pamela. "Uncertain honor: modern motherhood in an African crisis ? By Jennifer Johnson-Hanks." Journal of the Royal Anthropological Institute 13, no. 1 (March 2007): 238–39. http://dx.doi.org/10.1111/j.1467-9655.2007.00423_15.x.
Full text
12
Davey, Eleanor. "The Battle for Algeria: Sovereignty, Health Care, and Humanitarianism, by Jennifer Johnson." Journal of Refugee Studies 30, no. 1 (March 2017): 149–51. http://dx.doi.org/10.1093/jrs/fex004.
Full text
13
Varley, Emma. "The Battle for Algeria: Sovereignty, Health Care, and Humanitarianism by Jennifer Johnson." Journal of Global South Studies 33, no. 2 (2016): 115–19. http://dx.doi.org/10.1353/gss.2016.0041.
Full text
14
Crowley, Patrick. "The Battle for Algeria: Sovereignty, Health Care, and Humanitarianism. By Jennifer Johnson." French Studies 71, no. 2 (March 21, 2017): 298–99. http://dx.doi.org/10.1093/fs/knx050.
Full text
15
Bernardi, Laura. "Jennifer Johnson-Hanks (ed.), Uncertain Honor. Modern Motherhood in an African Crisis." European Journal of Population / Revue européenne de Démographie 23, no. 2 (March 29, 2007): 209–11. http://dx.doi.org/10.1007/s10680-007-9118-6.
Full text
16
Reynolds, Siân. "Anne Johnstone, Jennifer Cunningham & Russell Leadbetter, A Century of Care: Erskine 1916-2016." Clio, no. 49 (July 1, 2019): 288–90. http://dx.doi.org/10.4000/clio.16657.
Full text
17
Balaev, Michelle. "Reply." PMLA/Publications of the Modern Language Association of America 127, no. 4 (October 2012): 1017–18. http://dx.doi.org/10.1632/s0030812900121777.
Full textAbstract:
I appreciate Harold Fromm's emphasis on the diverse approaches found in the ecocritical field and on the relevance of ecocriticism to the goals and activities of the MLA because this was the future envisioned by the early scholars. Ecocriticism is an expansive, interdisciplinary field of study that arose from a shared desire for a new literary theory and practice. This shared interest has made ecocriticism a robust field that continues to grow, as seen in the newest ecocriticism program in the United States: the literature-and-environment program that started in the fall of 2012 in the English department at the University of Idaho, spearheaded by Scott Slovic, Jennifer Ladino, Erin James, Janis Johnson, and Jodie Nicotra. The field is also becoming rooted as an academic discipline around the world, in countries such as China, India, Brazil, and Australia, to name only a few.
18
Grøn, Lone, and Else Ladekjær. "The Institutional Aging Process. Ethnographic Explorations of Aging Processes and Dimensions in Danish Schools and Eldercare Institutions." Anthropology & Aging 38, no. 1 (June 6, 2017): 1–16. http://dx.doi.org/10.5195/aa.2017.139.
Full textAbstract:
In this paper, we will present an analysis of the institutional aging process in childhood and old age in contemporary Denmark. We will take as our point of departure Jennifer Johnson-Hanks’s observation that aging should be seen both as an experiential and an institutional process, and we will apply Ingold’s topographical phenomenology and his notions of maps, landscapes and wayfaring to our ethnographic data. Drawing on field work in Danish schools and elder care institutions, we explore aging processes through their spatial organizations and progressions. We sum up by reflecting on the similarities and differences between aging processes in early and late life. We argue that even if the institutional aging process can be seen as a map of the aging landscape – which acts as a powerful construct in experiences and practices of aging – wayfaring through that same landscape takes place between several poles: chronological, biological, social and phenomenological age – and involves considerable creativity and ongoing work and negotiation from both children and elderly.
19
Myles, David, and Kelly Lewis. "Constructing Injustice Symbols in Contemporary Trans Rights Activisms." Kvinder, Køn & Forskning, no. 3-4 (September 30, 2019): 24–42. http://dx.doi.org/10.7146/kkf.v28i2-3.116306.
Full textAbstract:
In this paper, we investigate the role that mourning and commemoration practices play in contemporary trans rights activism. Drawing from visual politics, digital activist culture, as well as media and communication, we analyse how trans rights movements construct injustice symbols that are used for sociopolitical mobilisation and expression. We contend that these symbols are constructed through shared communicative practices, which produce and circulate visuals that possess important memetic qualities (pictures, slogans, hashtags, graffiti, posters, etc.). To do so, we analyse three case studies where the unjust death of a trans person was collectively mobilised for political purposes: Jennifer Laude (Philippines, 1988-2014), Hande Kader (Turkey, 1993-2016), and Marsha P. Johnson (United States of America, 1945-1992). While each case study points to local or national specificities, our comparative analysis also underlines transnational trends in the production of posthumous visuals within contemporary trans rights activism. We conclude by addressing the contentions over the construction of trans symbols who inherently possess intersectional identities.
20
Imhof, Rüdiger. "«A Little Bit of Ivory, Two Inches Wide» : The Small World of Jennifer Johnston's Fiction." Études irlandaises 10, no. 1 (1985): 129–44. http://dx.doi.org/10.3406/irlan.1985.2337.
Full text
21
Thiel, Sara B. T. "Childhood, Education and the Stage in Early Modern England. Edited by Richard Preiss and Deanne Williams. Cambridge: Cambridge University Press, 2017; pp. xii + 296, 13 illustrations. $99 cloth, $80 e-book. - Queering Childhood in Early Modern English Drama and Culture. Edited by Jennifer Higginbotham and Mark Albert Johnston. New York: Palgrave Macmillan, 2018; pp. xiii + 281, 3 illustrations. $109 cloth, $84.99 e-book." Theatre Survey 60, no. 1 (December 21, 2018): 147–50. http://dx.doi.org/10.1017/s0040557418000534.
Full text
22
McIlwain, John K. "Comment on Jennifer Steffel Johnson and Emily Talen's “affordable housing in New Urbanist Communities: A survey of developers”." Housing Policy Debate 19, no. 4 (January 2008): 615–19. http://dx.doi.org/10.1080/10511482.2008.9521649.
Full text
23
Dietz, Robert D. "Comment on Jennifer Steffel Johnson and Emily Talen's “affordable housing in New Urbanist Communities: A survey of developers”." Housing Policy Debate 19, no. 4 (January 2008): 621–29. http://dx.doi.org/10.1080/10511482.2008.9521650.
Full text
24
Watson, David. "Failing States, Human (In)Security, and the American World Novel." New Global Studies 13, no. 1 (April 24, 2019): 80–101. http://dx.doi.org/10.1515/ngs-2019-0005.
Full textAbstract:
AbstractAs a growing number of contemporary American novelists take the world and its socio-cultural and geopolitical complexity as their subject matter, the contemporary novel’s form and sense of worldliness are shifting. Twenty-first century US fiction challenges normative models of the world proposed by theories of cosmopolitan relationality by projecting fragile worlds of strife and trauma, in which violence accompanies geopolitical turbulence. In these novels, discourses around human security—the everyday security needs of vulnerable populations—are increasingly prominent. Accordingly, contemporary US fiction often incorporates within its geopolitical imaginary such issues as human rights, humanitarian interventions, development, and how life is disabled by prejudice, civil war, scarcity, and health or other crises. In this essay, I range across a number of works by contemporary American novelists such as Dave Eggers, Jennifer Egan, Denis Johnson, Dana Spiotta, and Bob Shacochis in which state failures as well as human and geopolitical security concerns impact on the form given to the world by these novelists. In their novels, narratives concerning human security as well as threats to geopolitical stability produce transnational geographies in which global interconnections and circulation intensify feelings of insecurity.
25
Mease, P. J., T. Mallick-Searle, E. Johnston, L. Viktrup, D. Menuet, R. Yang, and R. J. Fountaine. "POS1088 EFFICACY OF SUBCUTANEOUS TANEZUMAB FOR THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE OR HIP: A POST-HOC SUBGROUP ANALYSIS OF PATIENTS FROM A RANDOMIZED, NSAID-CONTROLLED STUDY WITH A HISTORY OF DEPRESSION, ANXIETY, OR INSOMNIA." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 823–24. http://dx.doi.org/10.1136/annrheumdis-2021-eular.166.
Full textAbstract:
Background:Tanezumab is a monoclonal antibody directed against nerve growth factor. It is in development for the treatment of moderate to severe chronic pain associated with osteoarthritis (OA) in adult patients for whom other treatments are ineffective or not appropriate. Phase 3 clinical trials have demonstrated the efficacy of subcutaneous tanezumab versus placebo for pain and function outcomes over various timepoints. Largely similar change from baseline was demonstrated in an oral nonsteroidal anti-inflammatory drug (NSAID)-controlled study.1,2,3,4 The efficacy of some other OA therapies can be dampened in patients with depression, anxiety, or insomnia.5,6,7Objectives:A post-hoc analysis to explore the efficacy of subcutaneous tanezumab after 16 weeks treatment, as compared to oral NSAID, in patients with OA and a history of depression, anxiety, or insomnia at baseline.Methods:Subgroup analysis of data from a randomized, double-blind, double-dummy, active-controlled phase 3 study of subcutaneous tanezumab (2.5 mg or 5 mg every 8 weeks) vs twice daily oral NSAID in patients (≥18 years) with radiographically-confirmed moderate to severe hip or knee OA (Kellgren-Lawrence grade ≥2; NCT02528188).4 Co-primary efficacy endpoints were change from baseline to week 16 in Western Ontario and McMaster Universities OA Index (WOMAC*) Pain and Physical Function subscale scores (both ≥5/10 at randomisation; increasing score indicates increasing pain/disability), and Patient’s Global Assessment of OA (PGA-OA, ≥3/5 at randomisation; increasing score indicates poorer condition). Enrolled patients had a history of inadequate pain relief with acetaminophen; inadequate pain relief with/intolerance to/contraindication to tramadol or opioids; or an unwillingness to take opioids. Patients were on a stable dose of NSAID for ≥30 days before screening. Data are presented as least squares (LS) mean change from baseline to week 16 for the whole population and for subgroups of patients with/without a history of depression, anxiety, or insomnia at baseline. Exploratory statistical analysis was conducted by analysis of covariance. P values were not adjusted for multiplicity. This exploratory post-hoc analysis was not part of the pre-specified hypothesis testing plan or included in any sample size calculations; therefore, comparisons between treatment arms or patient subgroups should be interpreted with caution.Results:Overall, 2996 patients were randomized and received at least one dose of study treatment (subcutaneous tanezumab 2.5 mg: n=1002; subcutaneous tanezumab 5 mg: n=998; oral NSAID: n=996). In this population (comprising patients with or without a history of anxiety, depression or insomnia), all treatments were associated with notable and largely similar magnitude improvements in WOMAC Pain, WOMAC Physical Function, and PGA-OA at week 16 (Figure 1). Across treatment groups, differences in LS mean change from baseline in patients with and without a history of depression, anxiety or insomnia ranged between 0 - 0.34 for WOMAC Pain and Physical Function and 0 - 0.19 for PGA-OA.Conclusion:Patients with a history of depression, anxiety, or insomnia did not appear to experience dampened improvements in pain or function with tanezumab or NSAID, as compared to those without.References:[1]Schnitzer T, et al. JAMA. 2019;322(1):37-48;[2]Berenbaum F, et al. Ann Rheum Dis. 2020;79(6):800-10;[3]Schnitzer T, et al. Semin Arthritis Rheum. 2020;50(3):387-93;[4]Hochberg M, et al. Arthritis Rheumatol. In Press;[5]Sharma A, et al. Open Access Rheumatol. 2016;31(8):103-13;[6]Mallen C, et al. PLoS Med. 2017;14(4):e1002273;[7]Campbell C, et al. Arthritis Care Res. 2015;67(10):1387-96.Acknowledgements:Study sponsored by Pfizer and Eli Lilly and Company. Editorial support was provided by Jennifer Bodkin of Engage Scientific Solutions and funded by Pfizer and Eli Lilly and Company.Disclosure of Interests:Philip J Mease Speakers bureau: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Janssen, Eli Lilly and Company, Novartis, Pfizer, UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Galapagos, Gilead, GlaxoSmithKline, Janssen, Eli Lilly and Company, Novartis, Pfizer, Sun, UCB, Grant/research support from: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Janssen, Eli Lilly and Company, Novartis, Pfizer, Sun, UCB, Theresa Mallick-Searle Speakers bureau: Allergan, Abbvie, Eli Lilly and Company, Salix, Consultant of: Pfizer, Eli Lilly and Company, Elizabeth Johnston Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Lars Viktrup Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Dominique Menuet Employee of: Pfizer, Ruoyong Yang Employee of: Pfizer, Robert J Fountaine Shareholder of: Pfizer, Employee of: Pfizer.
26
Mara Reisman. "Renegotiating Relationships between Mothers and Daughters in Jennifer Johnston's The Invisible Worm and The Illusionist." Frontiers: A Journal of Women Studies 35, no. 2 (2014): 59. http://dx.doi.org/10.5250/fronjwomestud.35.2.0059.
Full text
27
Flynn, Karen. "The Reverend Jennie Johnson and African-Canadian History, 1868–1967.by Nina Reid-Maroney." Women's Studies 44, no. 3 (April 3, 2015): 437–40. http://dx.doi.org/10.1080/00497878.2015.1009770.
Full text
28
Groome, Todd. "Sovereign Wealth Management. Jennifer Johnson-Calari and Malan Rietveld, eds. Central Banking Publications, 2007, ISBN 978-1-902-18246-9, 284 pages." Journal of Pension Economics and Finance 8, no. 2 (April 2009): 246–47. http://dx.doi.org/10.1017/s1474747209004028.
Full text
29
Walker, Barrington. "The Reverend Jennie Johnson and African Canadian History, 1868–1967The Reverend Jennie Johnson and African Canadian History, 1868–1967. Nina Reid-Maroney. Rochester, NY: University of Rochester Press, 2013. Pp. x + 186, US $90.00 cloth." Canadian Historical Review 96, no. 2 (June 2015): 313–15. http://dx.doi.org/10.3138/chr.96.2.br13.
Full text
30
Huinink, Johannes. "Jennifer A. Johnson-Hanks, Christine A. Bachrach, S. Philip Morgan, Hans-Peter Kohler: Understanding Family Change and Variation. Toward a Theory of Conjunctural Action." European Journal of Population / Revue européenne de Démographie 28, no. 2 (May 2012): 235–37. http://dx.doi.org/10.1007/s10680-012-9263-4.
Full text
31
Touma, Z., B. Hoskin, C. Atkinson, D. Bell, O. Massey, J. H. Lofland, P. Berry, C. Karyekar, and K. Costenbader. "SAT0213 IMPACT OF FLARES ON HEALTHCARE RESOURCE USAGE AND PROS IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1049.2–1050. http://dx.doi.org/10.1136/annrheumdis-2020-eular.6010.
Full textAbstract:
Background:The effect of flares on healthcare resource usage and patient-reported outcome scores in SLE patients is not well quantified.Objectives:To understand how flares impact healthcare resource utilization (HCRU) and patient-reported outcomes amongst an international real-world dataset of SLE patients.Methods:The Adelphi Real World 2015 Lupus Disease Specific Programme (DSP) is a cross-sectional study of 263 rheumatologists in the US and EU5. Rheumatologists were asked to complete patient record forms (PRFs) for the next 5 prospectively consulting SLE patients; the same patients were asked to complete patient self-completion (PSC) forms describing how SLE affected them. PRFs collected data pertaining to the patient’s diagnosis, disease history, current clinical outcomes, treatment and management history. PSCs collected similar data and included patient-reported outcome measures (PROs) to assess humanistic burden. Propensity score matching was used to assess differences in HCRU and health status between SLE patients who had flared (physician defined) in the last 12 months and those who had not. Matching variables were patient ethnicity, time since diagnosis, and severity at diagnosis. Data were extracted from 1278 PRFs, and 591 PSCs. Propensity score matching was carried out on two matched groups of 408 patients.Results:Demographic data are reported in Table 1. Propensity score matching showed patients who flared in the last 12 months experienced significantly greater hospitalizations, visits to the ER, and total HCP consults in the last 12 months. Significantly greater drug burden lower physician and patient satisfaction, lower EQ-5D score (worse health status), lower FACIT Fatigue score (greater fatigue), and greater overall work impairment (Table 2) were also observed.Table 1.Demographic dataVariableFlared in last 12 monthsNot flared in the last 12 monthsMean age (years)41.842.4% Female86.087.0% White/Caucasian66.276.3Mean years diagnosed5.95.4Table 2.Propensity score matching resultsOutcome variableFlared meanNot flared meanCoefficient95% CIp-valueHospitalisations in last 12 months24.267.630.17[0.12 – 0.21]<0.001Emergency department visits in last 12 months20.834.190.17[0.12 – 0.21]<0.001Number of tests in last 12 months46.4938.907.59[3.74 – 11.44]<0.001Number of current medications2.762.190.57[0.43 – 0.72]<0.001Physician satisfied64.4686.63-0.22[-0.28 – -0.17]<0.001Patient satisfied69.2985.09-0.16[-0.24 – -0.08]<0.001EQ-5D-3L0.720.83-0.11[-0.15 – -0.07]<0.001FACIT Fatigue30.0636.48-6.42[-8.5 – -4.3]<0.001WPAI overall percentage work impairment42.7430.2312.5[7.51 – 17.50]<0.001Conclusion:The analysis of international real-world data confirmed that SLE patients who flared in the last year represent a greater burden on healthcare resource and demonstrate significantly worse health status, greater fatigue, lower patient and physician satisfaction and greater overall work impairment compared with non-flaring patients. There is a need for more effective treatments in this patient population to reduce patient and healthcare burden.Study funded by Johnson and Johnson.Disclosure of Interests:Zahi Touma Consultant of: Consultant for Janssen, Ben Hoskin Consultant of: Consultant for Janssen, Christian Atkinson Consultant of: Consultant for Janssen, David Bell Consultant of: Janssen, Olivia Massey Consultant of: Janssen, Jennifer H. Lofland Employee of: Janssen, Pamela Berry Employee of: Janssen, Chetan Karyekar Shareholder of: Johnson & Johnson, Consultant of: Janssen, Employee of: Janssen Global Services, LLC. Previously, Novartis, Bristol-Myers Squibb, and Abbott Labs., Karen Costenbader Grant/research support from: Merck, Consultant of: Astra-Zeneca
32
Kandane-Rathnayake, R., W. Louthrenoo, S. F. Luo, Y. J. Wu, Y. H. Chen, V. Golder, A. Lateef, et al. "AB0384 MEDICATION USE IN SYSTEMIC LUPUS ERYTHEMATOSUS – DATA FROM A MULTICENTRE COHORT STUDY." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1492–93. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3007.
Full textAbstract:
Background:In the absence of evidence-based treatment guidelines, medication use in SLE is highly variable. Low rates of remission and lupus low disease activity state (LLDAS) suggest that suboptimal responses to standard medications, which include glucocorticoids (GC), anti-malarial (AM) drugs and immunosuppressive (IS) agents, are common. Understanding the utility of current medications will facilitate the selection of patients for advanced therapies as they emerge.Objectives:To examine medication use patterns in a large multicentre SLE cohort.Methods:We used 2013-18 data from the Asia Pacific Lupus Collaboration (APLC) cohort in which disease activity (SLEDAI-2K) and medication details were captured at every visit. LLDAS was defined as in Golderet al., 2019 (1). We examined the use of medication (med) categories (GC &/or AM &/or IS) by SLE disease activity and LLDAS at the visit level. Additionally, we performed Cox regression analyses to determine the time-to-discontinuation of meds stratified by SLE disease activity, ranked by time-adjusted mean SLEDAI-2K, and by percent-time spent in LLDAS.Results:We analysed data from 19,804 visits of 2,860 patients. We observed 8 med categories: no meds; GC, AM or IS only; GC+AM; GC+IS; AM+IS and GC+AM+IS (triple therapy). Triple therapy was the most frequent med pattern (32%); single agents were used in 21% of visits and biologicals in only 3%. Among visits where SLEDAI-2K was ≥10, triple therapy was used in 46%, with median [IQR] GC dose 10 [6, 24] mg/day; in contrast, among visits with SLEDAI-2K≤4 triple therapy was used in 28% (p<0.01). Patients in LLDAS received less combination therapy than those who were not in LLDAS.Med persistence (survival analysis) varied widely, with lowest survivals for IS. Patients with time-adjusted mean SLEDAI-2K ≥10 had lower discontinuation of GC and higher discontinuation of IS including azathioprine, leflunomide and cyclosporine (Table 1). In contrast, increased time in LLDAS was associated with reduced discontinuation of AM and azathioprine.GCAMISMPhMPhAAZAMTXCyALEFOverall med survival, days to 25% discontinuation (95%CI)1048(938, 1197)1267(1113, 1428)175(175, 182)387(252, 756)409(350, 476)525(219, 686)268(182, 350)329(190, 524)Univariable associations,HR (95% CI) p-valueDisease activity≤41.001.001.001.001.001.001.001.00>4 & <100.69 (0.56,0.84)p<0.0011.15 (0.92,1.44)0.20.92 (0.80,1.05)0.21.37 (0.78,2.42)0.31.16 (0.97,1.39)0.111.11 (0.72,1.71)0.61.26 (0.90,1.77) 0.181.88 (1.07,3.30) 0.03≥100.65 (0.35,1.21) 0.181.56 (0.94,2.59) 0.080.84 (0.45,1.57)0.61.92 (0.80,4.63)0.142.69 (1.86,3.91) p<0.0011.85 (0.92,3.71) 0.082.66 (1.36,5.21) 0.0041.62 (1.13,2.32)0.009LLDAS<50%1.001.001.001.001.001.001.001.00≥50%1.30 (1.09, 1.55)0.0030.67 (0.54, 0.84)<0.0011.22 (1.08, 1.40)0.0020.83 (0.44,1.57)0.60.83 (0.69, 1.00)0.0540.70 (0.46, 1.07)0.101.29 (0.92, 1.83)0.140.43 (1.5, 1.25)0.12Conclusion:In a large multicentre SLE cohort, most patients were receiving combination treatment. AM treatment survival was high and associated with low disease activity, GC survival was high and associated with high disease activity, while IS survival was low. Patients with high disease activity received more medication combinations but had reduced IS survival. These data suggest ongoing unmet need for improved medications for treatment of SLE.Reference:Golder, V., et al Lancet Rheum. 2019 1(2):e95-102Disclosure of Interests:Rangi Kandane-Rathnayake Grant/research support from: The APLC has received financial (non-restricted educational) grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Janssen, EMD Serono, Eli Lilly and UCB for the LLDAS Validation Study., Worawit Louthrenoo: None declared, Shue Fen Luo: None declared, Yeong-Jian Wu Consultant of: Pfizer, Lilly, Novartis, Abbvie, Roche, Speakers bureau: Lilly, Novartis, Yi-Hsing Chen Grant/research support from: Taiwan Ministry of Science and Technology, Taiwan Department of Health, Taichung Veterans General Hospital, National Yang-Ming University, GSK, Pfizer, BMS., Consultant of: Pfizer, Novartis, Abbvie, Johnson & Johnson, BMS, Roche, Lilly, GSK, Astra& Zeneca, Sanofi, MSD, Guigai, Astellas, Inova Diagnostics, UCB, Agnitio Science Technology, United Biopharma, Thermo Fisher, Gilead., Paid instructor for: Pfizer, Novartis, Johnson & Johnson, Roche, Lilly, Astra& Zeneca, Sanofi, Astellas, Agnitio Science Technology, United Biopharma., Speakers bureau: Pfizer, Novartis, Abbvie, Johnson & Johnson, BMS, Roche, Lilly, GSK, Astra& Zeneca, Sanofi, MSD, Guigai, Astellas, Inova Diagnostics, UCB, Agnitio Science Technology, United Biopharma, Thermo Fisher, Gilead., Vera Golder: None declared, Aisha Lateef: None declared, Jiacai Cho: None declared, Sandra Navarra Speakers bureau: Astellas, Novartis, Pfizer, Johnson & Johnson, Abbvie, Leonid Zamora: None declared, Laniyati Hamijoyo Speakers bureau: Pfizer, Novartis, Tanabe, Abbot, Dexa Medica, Roche, Sargunan Sockalingam: None declared, Yuan An: None declared, Zhanguo Li: None declared, Yasuhiro Katsumata: None declared, masayoshi harigai Grant/research support from: AbbVie Japan GK, Ayumi Pharmaceutical Co., Bristol Myers Squibb Co., Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Co., Nippon Kayaku Co., Ltd., and Teijin Pharma Ltd. MH has received speaker’s fee from AbbVie Japan GK, Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan, Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Kissei Pharmaceutical Co., Ltd., Oxford Immuotec, Pfizer Japan Inc., and Teijin Pharma Ltd. MH is a consultant for AbbVie, Boehringer-ingelheim, Kissei Pharmaceutical Co., Ltd. and Teijin Pharma., Yanjie Hao: None declared, Zhuoli Zhang: None declared, Madelynn Chan: None declared, Jun Kikuchi: None declared, Tsutomu Takeuchi Grant/research support from: Eisai Co., Ltd, Astellas Pharma Inc., AbbVie GK, Asahi Kasei Pharma Corporation, Nippon Kayaku Co., Ltd, Takeda Pharmaceutical Company Ltd, UCB Pharma, Shionogi & Co., Ltd., Mitsubishi-Tanabe Pharma Corp., Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co. Ltd., Consultant of: Chugai Pharmaceutical Co Ltd, Astellas Pharma Inc., Eli Lilly Japan KK, Speakers bureau: AbbVie GK, Eisai Co., Ltd, Mitsubishi-Tanabe Pharma Corporation, Chugai Pharmaceutical Co Ltd, Bristol-Myers Squibb Company, AYUMI Pharmaceutical Corp., Eisai Co., Ltd, Daiichi Sankyo Co., Ltd., Gilead Sciences, Inc., Novartis Pharma K.K., Pfizer Japan Inc., Sanofi K.K., Dainippon Sumitomo Co., Ltd., Fiona Goldblatt: None declared, Sean O’Neill: None declared, Chetan Karyekar Shareholder of: Johnson & Johnson, Consultant of: Janssen, Employee of: Janssen Global Services, LLC. Previously, Novartis, Bristol-Myers Squibb, and Abbott Labs., Jennifer H. Lofland Employee of: Janssen, Sang-Cheol Bae: None declared, Chak Sing Lau: None declared, Alberta Hoi: None declared, Mandana Nikpour: None declared, Eric F. Morand Grant/research support from: AstraZeneca, Consultant of: AstraZeneca, Speakers bureau: AstraZeneca
33
Pint, Kris. "The Paleotechnology of Telephones and Screens." idea journal 17, no. 01 (October 21, 2020): 205–20. http://dx.doi.org/10.37113/ij.v17i01.383.
Full textAbstract:
This article argues that the essentials of the complex relationship between interiority and exteriority, and the mediating role of teletechnology, are already present in the interiors of Paleolithic caves. As philosopher Maxine Sheets-Johnstone argues in The Roots of Thinking (1990), cave art emerged from the primal fascination with ‘being inside.’ Yet at the same time, these first interiors were most likely created to establish a form of communication with an exterior, the ‘augmented reality’ of the spirit world, made possible through rudimentary technological and biological extensions. It also required a specific use of the spatial qualities of these caves, both sensory and atmospheric. This complex hybrid constellation of interior space, the human body and (psycho)technology created a permeability between different human and non-human actors. According to prehistorian Jean Clottes in Pourquoi l’art préhistorique (2011), the ‘permeability’ between inner and outer worlds is indeed one of the concepts that are crucial to understanding the Paleolithic human outlook on the environment, and is a concept which is still relevant today. Ever since these animistic Paleolithic works of art, teletechnology reveals what philosopher and literary theorist Jennifer Gosetti-Ferencei calls, in The Ecstatic Quotidian: Phenomenological Sightings in Modern Art and Literature (2007), the ‘ecstatic’ side of the quotidian. In this article, I follow the traces of this animistic, ecstatic experience in literature, in Walter Benjamin’s Berlin Childhood around 1900 (1932-8) and Marcel Proust’s In Search of Lost Time (1913-1927), and in cinematography, in Maya Deren’s Meshes of the Afternoon (1943) and David Cronenberg’s Videodrome (1983). The imagination of now outdated technologies creates a kind of anachronistic, defamiliarizing perspective that helps to grasp the animistic, mythical dimension of our daily domestic immersion in contemporary teletechnologies (from video chats to ASMR-videos). These anachronistic experiences we find in art allow us to better reflect on the ecstatic role of media-technology in relation to our spatial and psychological interiors, and the (psycho)technological conditions of contemporary dwelling in the interiors of the communication age.
34
Touma, Z., B. Hoskin, C. Atkinson, D. Bell, O. Massey, J. H. Lofland, P. Berry, C. Karyekar, and K. Costenbader. "THU0246 DIAGNOSTIC CLUSTER PROFILING OF PATIENTS IN A REAL-WORLD DATA SET WITH SYSTEMIC LUPUS ERYTHEMATOSUS." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 350.2–350. http://dx.doi.org/10.1136/annrheumdis-2020-eular.5865.
Full textAbstract:
Background:Previous systemic lupus erythematosus (SLE) studies have identified potential clusters of SLE clinical manifestations post diagnosis.Objectives:To describe the presentation of SLE at diagnosis across different cohorts of patients and describe management and outcomes after diagnosis within clusters.Methods:Cross-sectional study of 263 rheumatologists in the US and EU5. Data were collected from the Adelphi Real World 2015 Lupus Disease Specific Programme. Rheumatologists completed patient record forms (PRFs) for the next 5 prospectively consulting SLE patients; these patients completed patient self-completion (PSC) forms describing how SLE affected them. PRF data includes patient’s characteristics and management history. PSCs focused on similar data collection, including patient reported outcome measures on the humanistic burden. Age at diagnosis, symptoms at diagnosis, organ involvement at diagnosis, and severity at diagnosis were used as covariates in a latent cluster analysis.Results:Data were extracted from 1376 PRFs. Cluster analysis resulted in up to 6 clusters, and disease understanding led to the selection of a 4-cluster solution.Cluster 1 displayed the mildest disease, characterised by joint involvement, while cluster 2 displayed more skin involvement in conjunction with joint. Cluster 3 were characterised by renal involvement and cluster 4 had skin and joint involvement, but also high constitutional and haematological involvement at diagnosis (Table 1).Table 1Cluster analysisClustersOrgan involvement at diagnosis, n (%)Overall(n=1304)1(n=210)2(n=493)3(n=162)4(n=439)p-valueMusculoskeletal1145 (87.8)174 (82.9)444 (90.1)134 (82.7)393 (89.5)0.0065Mucocutaneous898 (68.9)5 (2.4)397 (80.5)95 (58.6)401 (91.3)<0.0001Neuropsychiatric87 (6.7)19 (9.0)9 (1.8)16 (9.9)43 (9.8)<0.0001Cardiorespiratory176 (13.5)36 (17.1)14 (2.8)22 (13.6)104 (23.7)<0.0001Gastrointestinal44 (3.4)8 (3.0)14 (2.8)8 (4.9)14 (3.2)0.6115Opthalmic47 (3.6)020 (4.1)10 (6.2)17 (3.9)0.0102Renal213 (16.6)15 (7.1)9 (1.8)162 (100)27 (6.2)<0.0001Constitutional425 (32.6)45 (21.4)89 (18.1)55 (34.0)236 (53.8)<0.0001Haematological452 (34.7)64 (30.5)22 (4.5)80 (49.4(286 (65.1)<0.0001Severity at diagnosis, n (%)Mild209 (16.0)55 (26.2)99 (20.1)1 (0.6)54 (12.3)<0.0001Moderate806 (61.8)122 (58.1)324 (65.7)75 (46.3)285 (64.9)Severe289 (22.2)33 (15.7)70 (14.2)86 (53.1)100 (22.8)Significant between-cluster differences were observed when comparing outcomes; cluster 4 have been diagnosed longest (mean weeks diagnosed 354.6 v. 1: 232.6, 2: 228.7, 3: 338.2, p<0.0001). Cluster 3 consulted more in the last 12 months (mean number of visits 7.9 vs. 1: 5.7, 2: 6.3, 4: 7.6).Significant differences were also observed between clusters in relation to current treatment proportions: corticosteroid (highest cluster 3: 78.4%), immunosuppressant (highest cluster 3: 75.3%), biologic DMARD (highest cluster 4: 17.8%) and antidepressant (highest cluster 4: 4.1%).Conclusion:This study demonstrates the heterogeneity of SLE at diagnosis and highlights four distinct presentations of the disease at diagnosis. Significant proportions of patients present with advanced disease, these clusters go on to present the greatest burden demonstrating the need for better diagnostic tools and novel earlier intervention.Study funded by Johnson and Johnson.Disclosure of Interests:Zahi Touma Consultant of: Consultant for Janssen, Ben Hoskin Consultant of: Consultant for Janssen, Christian Atkinson Consultant of: Consultant for Janssen, David Bell Consultant of: Janssen, Olivia Massey Consultant of: Janssen, Jennifer H. Lofland Employee of: Janssen, Pamela Berry Employee of: Janssen, Chetan Karyekar Shareholder of: Johnson & Johnson, Consultant of: Janssen, Employee of: Janssen Global Services, LLC. Previously, Novartis, Bristol-Myers Squibb, and Abbott Labs., Karen Costenbader Grant/research support from: Merck, Consultant of: Astra-Zeneca
35
Touma, Z., B. Hoskin, C. Atkinson, D. Bell, J. Pike, J. H. Lofland, P. Berry, C. Karyekar, and K. Costenbader. "AB1170 THE IMPACT OF HIGH DISEASE ACTIVITY AS MEASURED BY SLEDAI AND DRUG BURDEN-ON HEALTHCARE UTILIZATION, QUALITY OF LIFE AND WORK PRODUCTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1875.2–1876. http://dx.doi.org/10.1136/annrheumdis-2020-eular.5872.
Full textAbstract:
Background:Although there is abundant literature on healthcare utilization in SLE patients, the impact of disease activity in SLE patients is not well understood.Objectives:To quantify the impact of disease activity, as measured by SLEDAI score and drug burden, in SLE patients on health care resource utilization (HCRU), health related quality of life (HRQoL) and work productivity (WP).Methods:Data were collected from a cross-sectional survey of 754 rheumatologists in US and EU5 from the Adelphi Real World 2010/2013/2015 Lupus Disease Specific Programmes (DSP). Physicians were asked to complete patient record forms (PRFs) for the next 5 prospectively consulting SLE patients; the same patients were asked to complete patient self-completion (PSC) forms describing how SLE affected them. PRFs collected data pertaining to the patient’s diagnosis, disease history, current clinical outcomes, treatment and management history. PSCs focused on similar data collection and included patient reported outcome measures (PROs). Propensity score matching was used to assess differences in HCRU and PRO scores between SLE patients who had a low disease activity and those who had a high disease activity. Low disease activity was defined as a SLEDAI score of ≤4, a steroid dose of <7.5mg/day, and not on immunosuppressant or biologic. High disease activity was a SLEDAI score of >4, or on an immunosuppressant, biologic, or steroid dose of >7.5mg/day. Patients were matched on age, sex, and ethnicity.Results:Data was extracted from 1278 PRFs, and 591 PSCs. Using the estimated propensity score each low disease activity patient (n=44) was matched with a high disease activity patient (n=1187). Using 1:1 matching, with replacement and allowing for ties, matching resulted in 414 high disease activity patients being used as matches for 44 low disease activity patients. Demographic data are reported in Table 1. Patients with a low disease activity were significantly less likely to be currently flaring, lower number of flares in last 12 months, less likely to have been hospitalized in the last 12 months, had fewer consultations in the last 12 months, reported better HrQoL (EQ5D), more favourable levels of fatigue (FACIT), and lower work impairment (WPAI). (Table 2).Table 1.Demographic dataVariableLow disease activityHigh disease activityMean age (years)38.140.0% Female90.788.2% White/Caucasian76.767.7Mean years diagnosed5.55.0Table 1.Propensity score matching resultsOutcome variableLow activity meanHigh activity meanCoefficient95% CIp-valueFlared in the last 12 months11.6337.97-0.26[-0.38 – -0.14]<0.001Number of flares in last 12 months0.210.70-0.49[-0.72 - -0.26]<0.001Hospitalised in last 12 months4.6514.98-0.10[-0.17 – -0.04]0.001Number of consults in last 12 months2.843.52-0.68[-1.19 – -0.17]0.009EQ-5D-3L0.780.880.10[0.03 – 0.17]0.004FACIT Fatigue34.6839.865.19[0.80 – 9.57]0.02WPAI overall percentage work impairment14.4245.35-30.93[-45.32 – -16.54]<0.001Conclusion:Systemic lupus erythematosus patients with lower levels of disease activity are less burdensome to the healthcare system and experience a significantly better HRQoL and lower levels of productivity impairment. There is a need to establish a universal definition of low disease activity as a treatment goal to benefit patient quality of life and reduce HCRU.Study funded by Johnson and Johnson.Disclosure of Interests:Zahi Touma Consultant of: Consultant for Janssen, Ben Hoskin Consultant of: Consultant for Janssen, Christian Atkinson Consultant of: Consultant for Janssen, David Bell Consultant of: Janssen, James Pike Consultant of: Janssen, Jennifer H. Lofland Employee of: Janssen, Pamela Berry Employee of: Janssen, Chetan Karyekar Shareholder of: Johnson & Johnson, Consultant of: Janssen, Employee of: Janssen Global Services, LLC. Previously, Novartis, Bristol-Myers Squibb, and Abbott Labs., Karen Costenbader Grant/research support from: Merck, Consultant of: Astra-Zeneca
36
Namdaran, Kiarash, Deanna P. Bracy, D. Brooks Lacy, Janice L. Johnson, Jennifer L. Bupp, and David H. Wasserman. "Gut and liver fat metabolism in depancreatized dogs: effects of exercise and acute insulin infusion." Journal of Applied Physiology 83, no. 4 (October 1, 1997): 1339–47. http://dx.doi.org/10.1152/jappl.1997.83.4.1339.
Full textAbstract:
Namdaran, Kiarash, Deanna P. Bracy, D. Brooks Lacy, Janice L. Johnson, Jennifer L. Bupp, and David H. Wasserman. Gut and liver fat metabolism in depancreatized dogs: effects of exercise and acute insulin infusion. J. Appl. Physiol. 83(4): 1339–1347, 1997.—Excessive circulating fat levels are a defining feature of poor metabolic control in diabetes. Splanchnic adipose tissue is a source of free fatty acids (FFA), and the liver is a key site of FFA utilization and the sole source of ketones. Despite the role of splanchnic tissues in fat metabolism, little is known about how these tissues respond to diabetes under divergent metabolic conditions. Therefore, splanchnic fat metabolism was studied in poorly controlled diabetes under two conditions. First, it was studied during exercise, a stimulus that enhances FFA flux. Second, it was studied while insulin was being acutely infused to achieve levels normally present during exercise, a treatment that may be expected to inhibit lipolysis. For this purpose, liver and gut arteriovenous differences were used during rest and 2.5 h of treadmill exercise in insulin-deficient ( n = 6) and acutely insulin-infused ( n = 4) depancreatized (PX) dogs. The data show that 1) exercise, in insulin-deficient PX dogs, leads to an increase in net FFA release from mesenteric fat that is equal in magnitude to the response in nondiabetic dogs; 2) net hepatic fractional FFA extraction is increased twofold during exercise in both insulin-deficient PX dogs and nondiabetic control dogs; 3) during exercise, ∼40 and 75% of the FFA consumed by the liver is effectively transferred from fat stores mobilized from splanchnic adipose tissue in insulin-deficient PX and nondiabetic dogs, respectively; 4) hepatic ketogenic efficiency is elevated during rest three- to fourfold in insulin-deficient PX dogs compared with nondiabetic control dogs and remains elevated during exercise; and 5) surprisingly, acute insulin replacement is ineffective in normalizing net gut, hepatic, or splanchnic FFA or ketone body balances in PX dogs.
37
Naylor, Phillip C. "Jennifer Johnson . The Battle for Algeria: Sovereignty, Health Care, and Humanitarianism. Philadelphia: University of Pennsylvania Press, 2016. xiii + 270 pages, endnotes, references, index. Cloth US$75.00 ISBN 978-0-8122-4771-8." Review of Middle East Studies 51, no. 1 (February 2017): 106–8. http://dx.doi.org/10.1017/rms.2017.3.
Full text
38
EVERILL, BRONWEN. "HEALTH IN ALGERIA - The Battle for Algeria: Sovereignty, Health Care, and Humanitarianism. By Jennifer Johnson . Philadelphia: University of Pennsylvania Press, 2016. Pp. xiii + 270. $75.00, hardback (ISBN 978-0-8122-4771-8)." Journal of African History 58, no. 2 (June 7, 2017): 342–44. http://dx.doi.org/10.1017/s0021853717000135.
Full text
39
Broyld, Dann J. "Nina Reid-Maroney, The Reverend Jennie Johnson and African Canadian History, 1868–1967. Rochester: University of Rochester Press, 2013. Pp. 196. Cloth $90.00." Journal of African American History 100, no. 2 (April 2015): 328–31. http://dx.doi.org/10.5323/jafriamerhist.100.2.0328.
Full text
40
Ospina, Angela Jaramillo, Rosario Toro, Teresa Murguia-Peniche, Jennifer Wampler, Steven Wu, Carol Lynn Berseth, and Ricardo Uauy. "Growth Through 24 Months of Age in Infants Receiving Formulas with or Without Added Bovine Milk Fat Globule Membrane (MFGM) or Human Milk Through the First Year of Life: An RCT." Current Developments in Nutrition 4, Supplement_2 (May 29, 2020): 1014. http://dx.doi.org/10.1093/cdn/nzaa054_086.
Full textAbstract:
Abstract Objectives To evaluate growth through 24 months of age in infants receiving added bovine milk fat globule membrane (MFGM) in infant formula through 12 months of age. Concentration of MFGM from bovine milk fractions and incorporation in infant formula may better approximate the composition of complex milk lipids in human milk. Methods In the double-blind, randomized, controlled Chilean Infant Nutrition Trial (ChiNuT; NCT0262613), term infants whose mothers chose to initiate exclusive infant formula feeding before 4 months of age were randomized to receive: a standard cow's milk-based infant formula (SF, n = 174) or a similar formula with added whey protein-lipid concentrate (5 g/L; source of bovine MFGM) (bMFGM, n = 176). A reference group of infants exclusively receiving human milk (HM, n = 236) was also recruited. Growth through 24 months of age was the primary outcome. Length-for-age (LAZ), weight-for-age (WAZ) and body mass index (BMI)-for-age (BAZ) growth z-scores were analyzed by mixed-effects multiple linear regression models adjusted by sex, age (days), and maternal pregestational BMI (kg/m2). Results No significant group differences in sex, gestational age at birth, birthweight, maternal age and maternal education were detected, with the exception of maternal pregestational BMI (mean(SD)) (HM: 27.0(5.2) lower vs SF: 28.6(6.2) or bMFGM: 28.9(6.1); P = 0.002). Groups were similar at baseline (weight, length, WAZ, BAZ) with the exception of LAZ (lower in the bMFGM compared to HM group; P < 0.05). No significant differences in growth z-scores (absolute at 6, 9, 12, and 24 months of age or change between baseline and each study time point) were detected between SF and MFGM groups. Both randomized study formula groups were associated with higher growth z-score increases from baseline compared to the HM reference group between 6 and 24 months (P less than 0.05). Mean growth z-scores fell within the range of −1 to 1 (16th to 84th percentile) for SF, bMFGM, and HM groups at all study time points. Conclusions Added bovine MFGM in a routine cow's milk-based infant formula through 12 months of age supported normal growth through 24 months of age. Funding Sources The study was funded by Mead Johnson Nutrition (MJN). Teresa Murguia-Peniche, Steven Wu, and Jennifer Wampler are currently employed by MJN. Carol Lynn Berseth was previously employed by MJN.
41
Anderson, Jennifer L. "Patricia E. Kane, with Dennis Carr, Nancy Goyne Evans, Jennifer N. Johnson, and Gary R. Sullivan. Art and Industry in Early America: Rhode Island Furniture, 1650–1830. New Haven, CT: Yale University Press, 2016. xiii+508 pp.; 392 color illustrations, appendix, index. $85.00." Winterthur Portfolio 51, no. 4 (December 2017): 251–52. http://dx.doi.org/10.1086/697127.
Full text
42
Afridi, Faraz A., Jennifer Van Helmond, Rafat Ahmed, and Jaya Ganesh. "Hereditary Spherocytosis Due to a Novel Variant, P.Q1034X, in the Beta Subunit of the Spectrin Gene." Blood 136, Supplement 1 (November 5, 2020): 9–10. http://dx.doi.org/10.1182/blood-2020-134681.
Full textAbstract:
Introduction: Hereditary Spherocytosis (HS) is the most common red cell membrane disorder. 25-30% of cases involve the SPTB gene which encodes for β-Spectrin, a protein that maintains red blood cell shape. Heterozygous variants in SPTB are associated with autosomal dominant HS and elliptocytosis. While genetic testing is not routinely done to confirm HS, it is useful in atypical presentations. Case Description: A 1 week old male presented to the pediatric hematology/oncology clinic for anemia. He was born late preterm and had a history of hyperbilirubinemia requiring phototherapy, failure to thrive, and developmental delay. On examination, he was noted to have hypotonia. There was no known family history of hematologic problems. Based on this constellation of signs and symptoms, he had a comprehensive hematologic and genetic workup. On lab evaluation, his peripheral blood smear showed normocytic normochromic red blood cells with some spherocytes, significant polychromasia, normal WBC and normal platelet morphology. His newborn screen was normal, direct coombs' negative, osmotic fragility test was positive, and protein band 3 reduction was abnormal. His abdominal ultrasound was normal. Whole exome sequencing with variant segregation analysis was significant for heterozygosity of the p.Q1034X variant of the SPTB gene. This variant in the SPTB gene has not been previously reported. Discussion: We found a novel, de novo variant in an infant with HS through whole exome sequencing. This variant is predicted to cause loss of normal protein function either through protein truncation or non-mediated mRNA decay resulting in fragile red blood cells. While neither parent was found to carry this mutation, germline mosaicism should not be excluded. Physicians should be aware that prenatal diagnosis is available to address the risk of recurrence in future pregnancies. References: 1. Ankyrin-1 mutations are a major cause of dominant and recessive hereditary spherocytosis Stefan Eber-Jennifer Gonzalez-Marcia Lux-Alphonse Scarpa-William Tse-Marion Dornwell-Jutta Herbers-Wilfried Kugler-Refik Ozcan-Arnulf Pekrun-Patrick Gallagher-Werner Schroter-Bernard Forget-Samuel Lux - Nature Genetics - 1996 2. Characterization of the underlying molecular defect in hereditary spherocytosis associated with spectrin deficiency. H Hassoun-JN Vassiliadis-J Murray-PR Njolstad-JJ Rogus-SK Ballas-F Schaffer-P Jarolim-V Brabec-J Palek - Blood - 1997 3. The Complexity of Genotype-Phenotype Correlations in Hereditary Spherocytosis: A Cohort of 95 Patients Vuren-Annelies & Zwaag-Bert & Huisjes-Rick & Lak-Nathalie & Bierings-M.B. & Gerritsen-Egbert & van Beers-Eduard & Bartels-Marije & Van Wijk-Richard - HemaSphere - 2019 4. Hereditary spherocytosis with spectrin deficiency due to an unstable truncated beta spectrin. H Hassoun-JN Vassiliadis-J Murray-SJ Yi-M Hanspal-CA Johnson CA-J Palek - Blood - 1996 5. LL Peters- Semin Hematol-2018 6. Red cell membrane: past, present, and future Narla Mohandas-Patrick Gallagher - Blood - 2008 7. Spectrum of Ankyrin Mutations in Hereditary Spherocytosis: A Case Report and Review of the Literature Yeping Luo-Zhuoying Li-Lihua Huang-Jing Tian-Menglong Xiong-Zuocheng Yang - Acta Haematologica - 2018 Figure: A map of all the pathogenic mutations found on the protein structures of ankyrin-1, a-spectrin, b-spectrin and band 3. Figure Disclosures No relevant conflicts of interest to declare.
43
Elphick, Chris S. "Arctic Shorebirds in North America: A Decade of Monitoring. Studies in Avian Biology, Number 44. Edited by Jonathan Bart and Victoria Johnston; Associate Editors:, Paul A. Smith and Jennie Rausch. Berkeley (California): University of California Press. $80.00. xiii + 302 p.; ill.; index. ISBN: 978-0-520-27310-8. [A publication of the Cooper Ornithological Society.] 2012." Quarterly Review of Biology 89, no. 1 (March 2014): 73–74. http://dx.doi.org/10.1086/675045.
Full text
44
Deane, K., G. Firestein, D. Boyle, J. Buckner, E. A. James, S. Posso, W. Robinson, et al. "SAT0003 ELEVATED BASELINE AND INCREASING AUTOANTIBODY LEVELS ARE ASSOCIATED WITH INCREASED RISK FOR IMMINENT ONSET OF INFLAMMATORY ARTHRITIS IN A PROSPECTIVELY STUDIED ANTI-CITRULLINATED PROTEIN ANTIBODY POSITIVE COHORT: THE TIP-RA COLLECTIVE." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 932.1–932. http://dx.doi.org/10.1136/annrheumdis-2020-eular.5713.
Full textAbstract:
Background:The Targeting Immune Responses for Prevention of RA (TIP-RA) Collaborative prospectively studies individuals at high risk for developing RA because of serum ACPA positivity in absence of baseline inflammatory arthritis (IA).Objectives:The objective of the analyses presented herein is to evaluate the role of baseline and changing levels of ACPA and rheumatoid factor (RF) in relationship to incident IA/RA.Methods:ACPA+ subjects and ACPA- controls were identified who did not have baseline historical or examination evidence of IA. ACPA+ was defined by serum elevation of anti-CCP3 ≥20 units (Inova). Subjects were evaluated annually or sooner if they had changes in joint symptoms. Factors including RFIgM and RFIgA (Inova) were also assessed, and relationships between autoantibody levels at baseline and over time and incident IA/RA were evaluated using t-tests, with paired testing where applicable.Results:Baseline characteristics of ACPA+ and ACPA- subjects are in Table 1. Sixteen of the 94 (17%) ACPA+ subjects developed IA/RA a mean of 518 days from the baseline visit; 14 of these met 2010 ACR/EULAR criteria for RA at the time of detection of IA. There was a trend for ACPA+ subjects who later developed IA/RA to have higher baseline levels of anti-CCP3 compared to those who did not develop IA/RA (Table 2). In addition, those who developed IA/RA had significantly higher mean levels of RFIgM and RFIgA compared to those who did not. While not statistically significant, in longitudinal analyses in the ACPA+ subjects with incident IA/RA, anti-CCP3 levels increased from baseline to identification of IA (mean [SD] of 119 [102] to 126 [100], p=0.42). Furthermore, RFIgM levels increased from 36 [49] at baseline to 43 [51] at the time of IA (p=0.31), and RFIgA levels increased from 16 [29] to 21 [31] (p=0.10). In contrast, in ACPA+ subjects who did not develop IA/RA, anti-CCP3 levels increased only slightly over follow-up of a mean of 712 days: 75 [75] to 80 [76], p=0.70 while the levels of RFIgM and RFIgA decreased slightly during the same follow-up: for RFIgM mean [SD] levels went from 9 [22] to 8 [19], p=0.74; for RFIgA, 5 [16] to 3 [12], p=0.67.Table 1.Baseline characteristics of ACPA+/- subjectsACPA-(n=162)ACPA+(n=94)p-valueAge, mean58580.90% Female69680.67% Ever smoker33340.87RF-IgM, mean (SD)3.2 (10.0)13.5 (30.2)<0.01RF-IgA, mean (SD)0.3 (0.6)6.5 (19.1)<0.01Table 2.Baseline characteristics of 16 ACPA+ subjects who developed incident IA/RA vs. 78 ACPA+ who did notDid not develop IA/RA (n=78)Developed IA/RA (n=16)p-valueDays from baseline to IA/RA or follow-up, mean (SD)712 (124)518 (295)–% Meeting 2010 criteria at time of IA-88–CCP3, mean (SD)74.5 (75.3)119.1 (102.1)0.05RFIgM, mean (SD)9 (22)36 (49)<0.01RFIgA, mean (SD)4 (16)16 (29)0.03Conclusion:In this prospectively followed cohort of ACPA+ subjects, higher levels of RFIgM and RFIgA at baseline were significantly associated with development of IA/RA within the follow-up period. Furthermore, there was a trend for rising levels of anti-CCP3 and RFIgM and A to be associated with development of IA/RA. These finding support the use of higher and/or rising levels of autoantibodies as additional features to predict imminent onset of IA/RA in ACPA+ individuals as well as potentially to use as outcomes of success of preventive interventions. Furthermore, the trend of increasing levels of RFIgM and RFIgA over time in individuals who developed IA/RA suggests that targeting pathways of RF development may lead to preventive interventions in a subset of RA.References:NoneDisclosure of Interests:Kevin Deane Grant/research support from: Janssen, Consultant of: Inova, ThermoFisher, Janseen, BMS and Microdrop, Gary Firestein Grant/research support from: Lilly, Janssen, Abbvie, David Boyle: None declared, Jane Buckner Grant/research support from: Bristol-Myers Squibb, Janssen, Eddie A. James Grant/research support from: Janssen, Pfizer, Sanofi, Novartis, Sylvia Posso Grant/research support from: Janssen, William Robinson Grant/research support from: Janssen, Laurie K. Moss Grant/research support from: Janssen, Jennifer Seifert Grant/research support from: Janssen, Roger Gilmore Grant/research support from: Janssen, Saman Barzideh Grant/research support from: Janssen, Navin Rao Shareholder of: Janssen Pharmaceuticals, Employee of: Janssen Pharmaceuticals, Frederic Baribaud Shareholder of: Janssen Research & Development, LLC, Employee of: Janssen Research & Development, LLC, Sunil Nagpal Shareholder of: Janssen Pharmaceuticals, Employee of: Janssen Pharmaceuticals, Alyssa Johnsen Employee of: Janssen, V. Michael Holers Grant/research support from: Janssen, Celgene, and BMS
45
Horvath, Martine. "eye brings you another batch of the latest products and books on offerPersonal, Social and Emotional Development by Pat Broadhead, Jane Johnson, Caroline Tobbell, Richard Woolley (ISBN: 9781847065674). £16.99, Paperback. Published by Continuum Books. Tel: 020 72844009; www.continuumbooks.comHealthy Living Music Programme for Early Years Practitioners from Boogie Mites Resource pack including CD and booklet £30. Tel: 023 92817274; www.boogiemites.co.uk; enquiry@boogiemites.co.ukThe Key Person Approach by Jennie Lindon (ISBN: 9781907241079). Child-Initiated Learning by Jennie Lindon (ISBN: 9781907241062) Both books £12.50. Paperback. Published by Practical Pre-School Books. Tel: 01722 716935; www.practicalpreschoolbooks.com; orders@practicalpreschoolbooks.comWIN A DOLLS HOUSE from GALT Celebrate Galt's 175th anniversary, by entering this fabulous competition to win their Classic Victorian Dolls House and accessories worth £175.00…ideal for imaginative play! www.galt-educational.co.uk." Early Years Educator 12, no. 11 (March 2011): 47–48. http://dx.doi.org/10.12968/eyed.2011.12.11.47.
Full text
46
Suwahono, Suwahono, and Dwi Mawanti. "Using Environmentally Friendly Media (Happy Body) in Early Childhood Science: Human Body Parts Lesson." JPUD - Jurnal Pendidikan Usia Dini 13, no. 2 (December 5, 2019): 281–95. http://dx.doi.org/10.21009/jpud.132.06.
Full textAbstract:
The knowledge of the science of human body parts for early childhood is very important so that children have the ability to recognize and support the cleanliness and health of members of the body, as well as so that they recognize their identity. In addition, introducing environmentally friendly material for early childhood teachers to enrich learning media. This study aims to improve student learning outcomes in science using environmentally friendly media. The topic raised in this search was about recognizing body parts and their benefits and treatments. This type of research is action research. Respondents involved 19 early childhood students. The results showed that there was an increase in subjects' understanding of swallowing extremities and treatment 60% in the pre-cycle phase, 80% in the first cycle and 93% in the second cycle. The findings show that the use of happy body media has a positive effect on limb recognition. Further research is recommended on environmentally friendly media and ways of introducing limbs to early childhood through media or strategies suitable for the millennial era.
Keywords: Media (Happy Body), Early Childhood Science, Human Body Parts
References:
Anagnou, E., & Fragoulis, I. (2014). The contribution of mentoring and action research to teachers’ professional development in the context of informal learning. Review of European Studies, 6(1), 133–142.
Belsky, J., Steinberg, L., & Draper, P. (1991). Childhood experience, interpersonal development, and reproductive strategy: An evolutionary theory of socialization. Child Development, 62(4), 647.
Black, M. M., & Hurley, K. M. (2016). Early child development programmes: further evidence for action. The Lancet Global Health, 4(8), e505–e506.
Blok, H., Fukkink, R., Gebhardt, E., & Leseman, P. (2005). The relevance of delivery mode and other programme characteristics for the effectiveness of early childhood intervention. International Journal of Behavioral Development, 29(1), 35–47.
Borg, F., Winberg, M., & Vinterek, M. (2017). Children’s Learning for a Sustainable Society: Influences from Home and Preschool. Education Inquiry, 8(2), 151–172. https://doi.org/10.1080/20004508.2017.1290915
Borg, F., Winberg, T. M., & Vinterek, M. (2019). Preschool children’s knowledge about the environmental impact of various modes of transport. Early Child Development and Care, 189(3), 376–391. https://doi.org/10.1080/03004430.2017.1324433
Buchsbaum, D., Bridgers, S., Weisberg, D. S., &, & Gopnik, A. (2012). The power of possibility: Causal learning, counterfactual reasoning, and pretend play. Philosophical Transactions of the Royal Society. Biological Sciences, 367(1599), 2202–2212.
Burdette, H. L., & Whitaker, R. C. (2005). Resurrecting free play in young children: looking beyond fitness and fatness to attention, affiliation, and affect. Archives of Pediatrics & Adolescent Medicine, 159(1), 46–50.
Bustamante, A. S., White, L. J., & Greenfield, D. B. (2018). Approaches to learning and science education in Head Start: Examining bidirectionality. Early Childhood Research Quarterly, 44, 34–42. https://doi.org/10.1016/j.ecresq.2018.02.013
Carr, W. (2006). Philosophy, methodology and action research. Journal of Philosophy of Education, 40(4), 421–435.
Colker, L. J. (2008). Twelve characteristics of effective early childhood teachers. YC Young Children, 63(2).
Cook, C., Goodman, N. D., & Schulz, L. E. (2011). Where science starts: Spontaneous experiments in preschoolers’ exploratory play. Cognition, 120(3), 341– 349.
Dewi Kurnia, H. Z. (2017). Pentingnya Media Pembelajaran. Jurnal Pendidikan Anak Usia Dini, 1 No.1, 81–96.
Gelman, R., & Brenneman, K. (2004). Science learning pathways for young children. Early Childhood Research Quarterly, 19(1), 150–158.
Gersick, C. J. (1988). Time and transition in work teams: Toward a new model of group development. Academy of Management Journal, 31(1), 9–41.
Gopnik, A., Meltzoff, A. N., & Kuhl, P. K. (1999). The scientist in the crib: Mind, brains, and how children learn. New York, NY: William Morrow & Company.
Guo, Y., Wang, S., Hall, A. H., Breit-Smith, A., & Busch, J. (2016). The Effects of Science Instruction on Young Children’s Vocabulary Learning: A Research Synthesis. Early Childhood Education Journal, 44(4), 359–367. https://doi.org/10.1007/s10643-015-0721-6
Hadders-Algra, M. (2019). Interactive media use and early childhood development. Jornal de Pediatria, (xx), 1–3. https://doi.org/10.1016/j.jped.2019.05.001
Han, S., Capraro, R., & Capraro, M. M. (2015). How Science, Technology, Engineering, and Mathematics (Stem) Project-Based Learning (Pbl) Affects High, Middle, and Low Achievers Differently: the Impact of Student Factors on Achievement. International Journal of Science and Mathematics Education, 13(5), 1089–1113. https://doi.org/10.1007/s10763-014-9526-0
Harris, P. L., & Kavanaugh, R. D. (1993). Young children’s understanding of pretense. Monographs of the Society for Research in Child Development, 58(1), 1–92.
Hayati, H. S., Myrnawati, C. H., & Asmawi, M. (2017). Effect of Traditional Games, Learning Motivation And Learning Style On Childhoods Gross Motor Skills. International Journal of Education and Research, 5(7).
Hedefalk, M., Almqvist, J., & Östman, L. (2015). Education for sustainable development in early childhood education: a review of the research literature. Environmental Education Research, 21(7), 975–990. https://doi.org/10.1080/13504622.2014.971716
Herakleioti, E., & Pantidos, P. (2016). The Contribution of the Human Body in Young Children’s Explanations About Shadow Formation. Research in Science Education, 46(1), 21–42. https://doi.org/10.1007/s11165-014-9458-2
İlin, G., Kutlu, Ö., & Kutluay, A. (2013). An Action Research: Using Videos for Teaching Grammar in an ESP Class. Procedia - Social and Behavioral Sciences. https://doi.org/https://doi.org/10.1016/j.sbspro.2013.01.065
Jennifer M. Zosh, Emily J. Hopkins, Hanne Jensen, Claire Liu, Dave Neale, Kathy Hirsh-Pasek, S. L. S. and D. W. (2017). Learning through play : a review of the evidence.
Kagan, J., Reznick, J. S., & Snidman, N. (1987). The physiology and psychology of behavioral inhibition in children. Child Development, 1459–1473.
Kemmis, S., & Taggart, M. (2002). The action research planner. Victoria: Dearcin University Press.
Lebel, C., & Beaulieu, C. (2011). Longitudinal development of human brain wiring continues from childhood into adulthood. Journal of Neuroscience, 31(30), 10937–10947.
Luna, B., Garver, K. E., Urban, T. A., Lazar, N. A., & Sweeney, J. A. (2004). Maturation of cognitive processes from late childhood to adulthood. Child Development, 75(5), 1357–1372.
Nayfeld, I., Brenneman, K., & Gelman, R. (2011). Science in the classroom: Finding a balance between autonomous exploration and teacher-led instruction in preschool settings. Early Education & Development, 22(6), 970–988.
Nitecki, E., & Chung, M.-H. (2016). Play as Place: A Safe Space for Young Children to Learn about the World. Nternational Journal of Early Childhood Environmental Education, 4(1), 26–32.
Olgan, R. (2015). Influences on Turkish early childhood teachers’ science teaching practices and the science content covered in the early years. Early Child Development and Care, 185(6), 926-942.
Ramani, G. B. (2012). Influence of a Playful, Child-Directed Context on Preschool Children’s Peer Cooperation. New York: Merrill-Palmer Quarterly.
Ravanis, K. (2017). Early childhood science education: State of the art and perspectives. Journal of Baltic Science Education, 16(3), 284–288.
Russo-Johnson C, Troseth G, Duncan C, M. A. (2017). All tapped out: touchscreen interactivity and young children’s word learning. Front Psychology, 8.
Schulz, L. E., & Bonawitz, E. B. (2007). Serious fun: Preschoolers engage in more exploratory play when evidence is confounde. Developmental Psycholog, 43(4), 1045–1050.
Serpell, R., & Marfo, K. (2014). Some growth points in African child development research. New Directions for Child and Adolescent Development, 146, 97–112.
Vouloumanos, A., & Werker, J. F. (2007). Listening to language at birth: evidence for a bias for speech in neonates. Developmental Science, 10(2), 59–64.
Weisberg, D. S., & Gopnik, A. (2013). Pretense, counterfactuals, and Bayesian causal models: Why what is not real really matters. Cognitive Science, 37(7), 1368–1381.
Winthrop, R., & Mcgivney, E. (2016). Skills for a Changing World: Advancing Quality Learning for Vibrant Societies.Brookings: Center for Universal Education.
Zaman, B., & Eliyawati, C. (2010). Media Pembelajaran Anak Usia Dini. Bandung: Universitas Pendidikan Indonesia.
47
Greenhill, Jennifer. "Jennifer A. Greenhill. Review of "Seeing High and Low: Representing Social Conflict in American Visual Culture" by Patricia Johnston." caa.reviews, October 7, 2008. http://dx.doi.org/10.3202/caa.reviews.2008.99.
Full text
48
"Association News." PS: Political Science & Politics 46, no. 01 (January 2013): 183–84. http://dx.doi.org/10.1017/s1049096512001655.
Full textAbstract:
This year APSA celebrates the first decade of publication ofPerspectives on Politics. Added to the APSA journal portfolio in 2003,Perspectiveshas developed into an important publication for the discipline under the stewardship of its first three editors Jennifer Hochschild, Jim Johnson, and current editor Jeffrey C. Isaac and their respective editorial boards.
49
"International Stroke Conference 2013 Abstract Graders." Stroke 44, suppl_1 (February 2013). http://dx.doi.org/10.1161/str.44.suppl_1.aisc2013.
Full textAbstract:
Alex Abou-Chebl, MD Michael Abraham, MD Joseph E. Acker, III, EMT-P, MPH Robert Adams, MD, MS, FAHA Eric Adelman, MD Opeolu Adeoye, MD DeAnna L. Adkins, PhD Maria Aguilar, MD Absar Ahmed, MD Naveed Akhtar, MD Rufus Akinyemi, MBBS, MSc, MWACP, FMCP(Nig) Karen C. Albright, DO, MPH Felipe Albuquerque, MD Andrei V. Alexandrov, MD Abdulnasser Alhajeri, MD Latisha Ali, MD Nabil J. Alkayed, MD, PhD, FAHA Amer Alshekhlee, MD, MSc Irfan Altafullah, MD Arun Paul Amar, MD Pierre Amarenco, MD, FAHA, FAAN Sepideh Amin-Hanjani, MD, FAANS, FACS, FAHA Catherine Amlie-Lefond, MD Aaron M. Anderson, MD David C. Anderson, MD, FAHA Sameer A. Ansari, MD, PhD Ken Arai, PhD Agnieszka Ardelt, MD, PhD Juan Arenillas, MD PhD William Armstead, PhD, FAHA Jennifer L. Armstrong-Wells, MD, MPH Negar Asdaghi, MD, MSc, FRCPC Nancy D. Ashley, APRN,BC, CEN,CCRN,CNRN Stephen Ashwal, MD Andrew Asimos, MD Rand Askalan, MD, PhD Kjell Asplund, MD Richard P. Atkinson, MD, FAHA Issam A. Awad, MD, MSc, FACS, MA (hon) Hakan Ay, MD, FAHA Michael Ayad, MD, PhD Cenk Ayata, MD Aamir Badruddin, MD Hee Joon Bae, MD, PhD Mark Bain, MD Tamilyn Bakas, PhD, RN, FAHA, FAAN Frank Barone, BA, DPhil Andrew Barreto, MD William G. Barsan, MD, FACEP, FAHA Nicolas G. Bazan, MD, PhD Kyra Becker, MD, FAHA Ludmila Belayev, MD Rodney Bell, MD Andrei B. Belousov, PhD Susan L. Benedict, MD Larry Benowitz, PhD Rohit Bhatia, MBBS, MD, DM, DNB Pratik Bhattacharya, MD MPh James A. Bibb, PhD Jose Biller, MD, FACP, FAAN, FAHA Randie Black Schaffer, MD, MA Kristine Blackham, MD Bernadette Boden-Albala, DrPH Cesar Borlongan, MA, PhD Susana M. Bowling, MD Monique M. B. Breteler, MD, PhD Jonathan Brisman, MD Allan L. Brook, MD, FSIR Robert D. Brown, MD, MPH Devin L. Brown, MD, MS Ketan R. Bulsara, MD James Burke, MD Cheryl Bushnell, MD, MHSc, FAHA Ken Butcher, MD, PhD, FRCPC Livia Candelise, MD S Thomas Carmichael, MD, PhD Bob S. Carter, MD, PhD Angel Chamorro, MD, PhD Pak H. Chan, PhD, FAHA Seemant Chaturvedi, MD, FAHA, FAAN Peng Roc Chen, MD Jun Chen, MD Eric Cheng, MD, MS Huimahn Alex Choi, MD Sherry Chou, MD, MMSc Michael Chow, MD, FRCS(C), MPH Marilyn Cipolla, PhD, MS, FAHA Kevin Cockroft, MD, MSc, FACS Domingos Coiteiro, MD Alexander Coon, MD Robert Cooney, MD Shelagh B. Coutts, BSc, MB.ChB., MD, FRCPC, FRCP(Glasg.) Elizabeth Crago, RN, MSN Steven C. Cramer, MD Carolyn Cronin, MD, PhD Dewitte T. Cross, MD Salvador Cruz-Flores, MD, FAHA Brett L. Cucchiara, MD, FAHA Guilherme Dabus, MD M Ziad Darkhabani, MD Stephen M. Davis, MD, FRCP, Edin FRACP, FAHA Deidre De Silva, MBBS, MRCP Amir R. Dehdashti, MD Gregory J. del Zoppo, MD, MS, FAHA Bart M. Demaerschalk, MD, MSc, FRCPC Andrew M. Demchuk, MD Andrew J. DeNardo, MD Laurent Derex, MD, PhD Gabrielle deVeber, MD Helen Dewey, MB, BS, PhD, FRACP, FAFRM(RACP) Mandip Dhamoon, MD, MPH Orlando Diaz, MD Martin Dichgans, MD Rick M. Dijkhuizen, PhD Michael Diringer, MD Jodi Dodds, MD Eamon Dolan, MD, MRCPI Amish Doshi, MD Dariush Dowlatshahi, MD, PhD, FRCPC Alexander Dressel, MD Carole Dufouil, MD Dylan Edwards, PhD Mitchell Elkind, MD, MS, FAAN Matthias Endres, MD Joey English, MD, PhD Conrado J. Estol, MD, PhD Mustapha Ezzeddine, MD, FAHA Susan C. Fagan, PharmD, FAHA Pierre B. Fayad, MD, FAHA Wende Fedder, RN, MBA, FAHA Valery Feigin, MD, PhD Johanna Fifi, MD Jessica Filosa, PhD David Fiorella, MD, PhD Urs Fischer, MD, MSc Matthew L. Flaherty, MD Christian Foerch, MD Gregg C. Fonarow, MD, FAHA Andria Ford, MD Christine Fox, MD, MAS Isabel Fragata, MD Justin Fraser, MD Don Frei, MD Gary H. Friday, MD, MPH, FAAN, FAHA Neil Friedman, MBChB Michael Froehler, MD, PhD Chirag D. Gandhi, MD Hannah Gardener, ScD Madeline Geraghty, MD Daniel P. Gibson, MD Glen Gillen, EdD, OTR James Kyle Goddard, III, MD Daniel A. Godoy, MD, FCCM Joshua Goldstein, MD, PhD, FAHA Nicole R. Gonzales, MD Hector Gonzalez, PhD Marlis Gonzalez-Fernandez, MD, PhD Philip B. Gorelick, MD, MPH, FAHA Matthew Gounis, PhD Prasanthi Govindarajan, MD Manu Goyal, MD, MSc Glenn D. Graham, MD, PhD Armin J. Grau, MD, PhD Joel Greenberg, PhD, FAHA Steven M. Greenberg, MD, PhD, FAHA David M. Greer, MD, MA, FCCM James C. Grotta, MD, FAHA Jaime Grutzendler, MD Rishi Gupta, MD Andrew Gyorke, MD Mary N. Haan, MPH, DrPH Roman Haberl, MD Maree Hackett, PhD Elliot Clark Haley, MD, FAHA Hen Hallevi, MD Edith Hamel, PhD Graeme J. Hankey, MBBS, MD, FRCP, FRCP, FRACP Amer Haque, MD Richard L. Harvey, MD Don Heck, MD Cathy M. Helgason, MD Thomas Hemmen, MD, PhD Dirk M. Hermann, MD Marta Hernandez, MD Paco Herson, PhD Michael D. Hill, MD, MSc, FRCPC Nancy K. Hills, PhD, MBA Robin C. Hilsabeck, PhD, ABPP-CN Judith A. Hinchey, MD, MS, FAHA Robert G. Holloway, MD, MPH William Holloway, MD Sherril K. Hopper, RN Jonathan Hosey, MD, FAAN George Howard, DPH, FAHA Virginia J. Howard, PhD, FAHA David Huang, MD, PhD Daniel Huddle, DO Richard L. Hughes, MD, FAHA, FAAN Lynn Hundley, RN, MSN, ARNP, CCRN, CNRN, CCNS Patricia D. Hurn, PhD, FAHA Muhammad Shazam Hussain, MD, FRCPC Costantino Iadecola, MD Rebecca N. Ichord, MD M. Arfan Ikram, MD Kachi Illoh, MD Pascal Jabbour, MD Bharathi D. Jagadeesan, MD Vivek Jain, MD Dara G. Jamieson, MD, FAHA Brian T. Jankowitz, MD Edward C. Jauch, MD, MS, FAHA, FACEP David Jeck, MD Sayona John, MD Karen C. Johnston, MD, FAHA S Claiborne Johnston, MD, FAHA Jukka Jolkkonen, PhD Stephen C. Jones, PhD, SM, BSc Theresa Jones, PhD Anne Joutel, MD, PhD Tudor G. Jovin, MD Mouhammed R. Kabbani, MD Yasha Kadkhodayan, MD Mary A. Kalafut, MD, FAHA Amit Kansara, MD Moira Kapral, MD, MS Navaz P. Karanjia, MD Wendy Kartje, MD, PhD Carlos S. Kase, MD, FAHA Scott E. Kasner, MD, MS, FAHA Markku Kaste, MD, PhD, FESO, FAHA Prasad Katakam, MD, PhD Zvonimir S. Katusic, MD Irene Katzan, MD, MS, FAHA James E. Kelly, MD Michael Kelly, MD, PhD, FRCSC Peter J. Kelly, MD, MS, FRCPI, ABPN (Dip) Margaret Kelly-Hayes, EdD, RN, FAAN David M. Kent, MD Thomas A. Kent, MD Walter Kernan, MD Salomeh Keyhani, MD, MPH Alexander Khalessi, MD, MS Nadia Khan, MD, FRCPC, MSc Naim Naji Khoury, MD, MS Chelsea Kidwell, MD, FAHA Anthony Kim, MD Howard S. Kirshner, MD, FAHA Adam Kirton, MD, MSc, FRCPC Brett M. Kissela, MD Takanari Kitazono, MD, PhD Steven Kittner, MD, MPH Jeffrey Kleim, PhD Dawn Kleindorfer, MD, FAHA N. Jennifer Klinedinst, PhD, MPH, MSN, RN William Knight, MD Adam Kobayashi, MD, PhD Sebastian Koch, MD Raymond C. Koehler, PhD, FAHA Ines P. Koerner, MD, PhD Martin Köhrmann, MD Anneli Kolk, PhD, MD John B. Kostis, MD Tobias Kurth, MD, ScD Peter Kvamme, MD Eduardo Labat, MD, DABR Daniel T. Lackland, BA, DPH, FAHA Kamakshi Lakshminarayan, MD, PhD Joseph C. LaManna, PhD Catherine E. Lang, PT, PhD Maarten G. Lansberg, MD, PhD, MS Giuseppe Lanzino, MD Paul A. Lapchak, PhD, FAHA Sean Lavine, MD Ronald M. Lazar, PhD Marc Lazzaro, MD Jin-Moo Lee, MD, PhD Meng Lee, MD Ting-Yim Lee, PhD Erica Leifheit-Limson, PhD Enrique Leira, MD, FAHA Deborah Levine, MD, MPh Joshua M. Levine, MD Steven R. Levine, MD Christopher Lewandowski, MD Daniel J. Licht, MD Judith H. Lichtman, PhD, MPH David S. Liebeskind, MD, FAHA Shao-Pow Lin, MD, PhD Weili Lin, PhD Ute Lindauer, PhD Italo Linfante, MD Lynda Lisabeth, PhD, FAHA Alice Liskay, RN, BSN, MPA, CCRC Warren Lo, MD W. T. Longstreth, MD, MPH, FAHA George A. Lopez, MD, PhD David Loy, MD, PhD Andreas R. Luft, MD Helmi Lutsep, MD, FAHA William Mack, MD Mark MacKay, MBBS, FRACP Jennifer Juhl Majersik, MD Marc D. Malkoff, MD, FAHA Randolph S. Marshall, MD John H. Martin, PhD Alexander Mason, MD Masayasu Matsumoto, MD, PhD Elizabeth Mayeda, MPH William G. Mayhan, PhD Avi Mazumdar, MD Louise D. McCullough, MD, PhD Erin McDonough, MD Lisa Merck, MD, MPH James F. Meschia, MD, FAHA Steven R. Messe, MD Joseph Mettenburg, MD,PhD William Meurer, MD BA Brett C. Meyer, MD Robert Mikulik, MD, PhD James M. Milburn, MD Kazuo Minematsu, MD, PhD J Mocco, MD, MS Yousef Mohammad, MD MSc FAAN Mahendranath Moharir, MD, MSc, FRACP Carlos A. Molina, MD Joan Montaner, MD PhD Majaz Moonis, MD, MRCP Christopher J. Moran, MD Henry Moyle, MD, PhD Susanne Muehlschlegel, MD, MPH Susanne Muehlschlegel, MD, MPH Yuichi Murayama, MD Stephanie J. Murphy, VMD, PhD, DACLAM, FAHA Fadi Nahab, MD Andrew M. Naidech, MD, MPh Ashish Nanda, MD Sandra Narayanan, MD William Neil, MD Edwin Nemoto, PhD, FAHA Lauren M. Nentwich, MD Perry P. Ng, MD Al C. Ngai, PhD Andrew D. Nguyen, MD, PhD Thanh Nguyen, MD, FRCPC Mai Nguyen-Huynh, MD, MAS Raul G. Nogueira, MD Bo Norrving, MD Robin Novakovic, MD Thaddeus Nowak, PhD David Nyenhuis, PhD Michelle C. Odden, PhD Michael O'Dell, MD Christopher S. Ogilvy, MD Jamary Oliveira-Filho, MD, PhD Jean Marc Olivot, MD, PhD Brian O'Neil, MD, FACEP Bruce Ovbiagele, MD, MSc, FAHA Shahram Oveisgharan, MD Mayowa Owolabi, MBBS,MWACP,FMCP Aditya S. Pandey, MD Dhruvil J. Pandya, MD Nancy D. Papesh, BSN, RN, CFRN, EMT-B Helena Parfenova, PhD Min S. Park, MD Matthew S. Parsons, MD Aman B. Patel, MD Srinivas Peddi, MD Joanne Penko, MS, MPH Miguel A. Perez-Pinzon, PhD, FAHA Paola Pergami, MD, PhD Michael Phipps, MD Anna M. Planas, PhD Octavio Pontes-Neto, MD Shyam Prabhakaran, MD, MS Kameshwar Prasad, MD, DM, MMSc, FRCP, FAMS Charles Prestigiacomo, MD, FAANS, FACS G. Lee Pride, MD Janet Prvu Bettger, ScD, FAHA Volker Puetz, MD, PhD Svetlana Pundik, MD Terence Quinn, MD, MRCP, MBChb (hons), BSc (hons) Alejandro Rabinstein, MD Mubeen Rafay, MB.BS, FCPS, MSc Preeti Raghavan, MD Venkatakrishna Rajajee, MD Kumar Rajamani, MD Peter A. Rasmussen, MD Kumar Reddy, MD Michael J. Reding, MD Bruce R. Reed, PhD Mathew J. Reeves, BVSc, PhD, FAHA Martin Reis, MD Marc Ribo, MD, PhD David Rodriguez-Luna, MD, PhD Charles Romero, MD Jonathan Rosand, MD Gary A. Rosenberg, MD Michael Ross, MD, FACEP Natalia S. Rost, MD, MA Elliot J. Roth, MD, FAHA Christianne L. Roumie, MD, MPH Marilyn M. Rymer, MD, FAHA Ralph L. Sacco, MS, MD, FAAN, FAHA Edgar A. Samaniego, MD, MS Navdeep Sangha, BS, MD Nerses Sanossian, MD Lauren Sansing, MD, MSTR Gustavo Saposnik, MD, MSc, FAHA Eric Sauvageau, MD Jeffrey L. Saver, MD, FAHA, FAAN Sean I. Savitz, MD, FAHA Judith D. Schaechter, PhD Lee H. Schwamm, MD, FAHA Phillip Scott, MD, FAHA Magdy Selim, MD, PhD, FAHA Warren R. Selman, MD, FAHA Souvik Sen, MD, MS, MPH, FAHA Frank Sharp, MD, FAHA, FAAN George Shaw, MD, PhD Kevin N. Sheth, MD Vilaas Shetty, MD Joshua Shimony, MD, PhD Yukito Shinohara, MD, PhD Ashfaq Shuaib, MD, FAHA Lori A. Shutter, MD Cathy A. Sila, MD, FAAN Gisele S. Silva, MD Brian Silver, MD Daniel E. Singer, MD Robert Singer, MD Aneesh B. Singhal, MD Lesli Skolarus, MD Eric E. Smith, MD Sabrina E. Smith, MD, PhD Christopher Sobey, PhD, FAHA J David Spence, MD Christian Stapf, MD Joel Stein, MD Michael F. Stiefel, MD, PhD Sophia Sundararajan, MD, PhD David Tanne, MD Robert W. Tarr, MD Turgut Tatlisumak, MD, PhD, FAHA, FESO Charles H. Tegeler, MD Mohamed S. Teleb, MD Fernando Testai, MD, PhD Ajith Thomas, MD Stephen Thomas, MD, MPH Bradford B. Thompson, MD Amanda Thrift, PhD, PGDipBiostat David Tong, MD Michel Torbey, MD, MPH, FCCM, FAHA Emmanuel Touze, MD, PhD Amytis Towfighi, MD Richard J. Traystman, PhD, FAHA Margaret F. Tremwel, MD, PhD, FAHA Brian Trimble, MD Georgios Tsivgoulis, MD Tanya Turan, MD, FAHA Aquilla S. Turk, DO Michael Tymianski, MD, PhD, FRCSC Philippa Tyrrell, MB, MD, FRCP Shinichiro Uchiyama, MD, FAHA Luis Vaca, MD Renee Van Stavern, MD Susan J. Vannucci, PhD Dale Vaslow, MD, PHD Zena Vexler, PhD Barbara Vickrey, MD, MPH Ryan Viets, MD Anand Viswanathan, MD, PhD Salina Waddy, MD Kenneth R. Wagner, PhD Lawrence R. Wechsler, MD Ling Wei, MD Theodore Wein, MD, FRCPC, FAHA Babu Welch, MD David Werring, PhD Justin Whisenant, MD Christine Anne Wijman, MD, PhD Michael Wilder, MD Joshua Willey, MD, MS David Williams, MB, BAO, BCh, PhD, Dip.Med.Tox, FRCPE, FRCPI Linda Williams, MD Olajide Williams, MD, MS Dianna Willis, PhD John A. Wilson, MD, FACS Jeffrey James Wing, MPH Carolee J. Winstein, PhD, PT, FAPTA Max Wintermark, MD Charles Wira, MD Robert J. Wityk, MD, FAHA Thomas J. Wolfe, MD Lawrence Wong, MD Daniel Woo, MD, MS Clinton Wright, MD, MS Guohua Xi, MD Ying Xian, MD, PhD Dileep R. Yavagal, MD Midori A. Yenari, MD, FAHA William L. Young, MD Darin Zahuranec, MD Allyson Zazulia, MD, FAHA Adina Zeki Al Hazzouri, PhD John H. Zhang, MD, PhD Justin Zivin, MD, PhD, FAHA Richard Zorowitz, MD, FAHA Maria Cristina Zurru, MD
50
"Jennifer A. Johnson-Hanks, Christine A. Bachrach, S. Philip Morgan, and Hans-Peter Kohler,Understanding Family Change and Variation: Toward a Theory of Conjunctural Action." Population and Development Review 40, no. 1 (March 2014): 173–74. http://dx.doi.org/10.1111/j.1728-4457.2014.00661.x.
Full text